ArticleNeuropsychiatric disease and treatment2024
Clinical Patterns of Metabolic Syndrome in First-Hospitalized Major Depressive Disorder Patients: Comparison of Antidepressant-Exposed and Drug-Naïve Groups.
Article in Neuropsychiatric disease and treatment, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Epigenetic Perspectives on Maternal Gut Microbiota's Impact on Embryonic and Fetal Development.Comprehensive Physiology · 2026Review
- Potential value of oral Mogibacterium in major depressive disorder.Frontiers in cellular and infection microbiology · 2026Article
- Exploring potential value of neutrophil extracellular traps in major depressive disorder.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Major depressive disorder (MDD) and metabolic syndrome (MetS) are both major health threats nowadays, and the relationship between them is complex and close. The purpose of this paper is to compare differences in the prevalence and risk factors of MetS in first hospitalized patients with MDD with and without antidepressant exposure. Methods: A total of 636 first hospitalized MDD patients (study group) with antidepressant exposure and 345 drug-naïve patients (control group) were included in this study. Their socio-demographic data, routine biochemical indices, and psychological symptom assessment were collected. Results: There was no difference in the prevalence of MetS between the study group and the control group (F = 2.49, p = 0.115). Factors affecting MetS and its severity differed between the two groups, in the study group, the identified risk factors for MetS were onset age (B = 0.05, p <0.001, OR = 1.05, 95% CI = 1.02-1.08), TSH level (B = 0.42, p <0.001, OR = 1.53, 95% CI = 1.39-1.68). Meanwhile, in the control group, the identified risk factors for MetS were more extensive and they were, onset age (B = 0.11, p <0.001, OR = 1.12, 95% CI = 1.07-1.16), suicidal behavior (B = 1.54, p = 0.007, OR = 4.65, 95% CI = 1.51-14.33), HAMD scores (B = 0.23, p = 0.008, OR = 1.26, 95% CI = 1.06-1.49) and TSH levels (B = 0.33, p <0.001, OR = 1.39, 95% CI = 1.17-1.65). The number of risk factors identified was lower in the study group. Conclusion: Antidepressant use was associated with greater MetS severity but did not affect overall prevalence. Antidepressants appear to modify MetS risk factors, highlighting the need to differentiate these effects from those in drug-naïve patients when developing MetS interventions for the MDD population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.